The agency's language was unambiguous: "Retatrutide and Cagrilintide cannot be used in compounding under federal law." [3,5] The letters cited multiple FDCA violations, including Section 505(a) (unapproved new drug), Section 502(f)(1) (inadequate directions for use), and Sections 301(a) and 301(d) (introduction into interstate commerce of an unapproved drug)
10.2337/diabetes.48.5.1045
By staying hydrated, increasing fiber, exercising regularly, and working closely with your healthcare provider, you can navigate this side effect while continuing to benefit from the medications weight loss and metabolic support
Our BMI requirements for GLP-1 guide details the specific thresholds
Exercise more regularly for example, by going for a daily walk
lipid peroxidation in experimental salmonella infection